Skip to main content

Table 2 Study characteristics of studies investigating the prognostic relevance of HPV-18

From: Prognostic implication of human papillomavirus types in cervical cancer patients: a systematic review and meta-analysis

Author Year Country Total number of patients Mean age Clinical stage Treatment Number of patients with HPV-18 positive Number of patients with HPV-18 negative Median DFS Median PFS Median OS
Yat Ming Lau 2015 Hong Kong, China 236 54.4 I-III radiotherapy+/−chemotherapy. 30 185 73.2% vs. 78.2%, HR: 1.49, 95% CI = 0.78–2.86 NA 80% vs. 75.7%, HR: 1.23, 95% CI = 0.66–2.27
Sun-Hye Yang 2014 Korea 116 NA I-IIA surgery 15 101 NA HR: 5.2, 95% CI = 1.29–20.9, P = 0.02 Not significant
Rossana de Arau ́jo Cata ̃o Zampronha 2013 Brazil 86 40 I Surgery+radiotherapy 25 51 HR: 0.797, 95% CI = 0.175–3.640 NA NA
Robert A. Burger 1996 USA 291 NA I-IV radical hysterectomy and pelvic lymphadenectomy 58 233 NA NA HR: 2.59, 95% CI = 1.08–6.22
Chyong-Huey Lai 2007 Taiwan, China 1067 50 IA-IIA surgery 176 891 HR: 1.8, 95% CI = 1.8–2.7   HR: 1.7, 95% CI = 1.1–2.6
Woo Dae Kang 2011 Korea 204 49 IB-IIA radical hysterectomy followed by adjuvant radiotherapy or primary radiotherapy with concurrent cisplatin-containing chemotherapy 28 176 NA HR: 2.664, 95% CI = 1.437–4.938 NA
Shizhuo Wang 2012 China 24,041 NA I-IV NA 2082 21,959 NA NA HR: 1.704, 95% CI = 1.095–2.654
  1. HPV Human papillomavirus, DFS Disease free survival, HR Hazard ratio, CI Confidence interval, NA Not available, DFS Disease free survival, PFS Progression free survival, OS Overall survival